Rituximab does not reset defective early B cell tolerance checkpoints.

Area of Science:

• Immunology
• Endocrinology
• Autoimmunity

Background:

• Type 1 diabetes (T1D) is linked to B cell tolerance defects, leading to autoreactive B cells.
• Anti-CD20 monoclonal antibody (mAb) therapy, like rituximab, depletes B cells and shows promise in T1D and other autoimmune diseases.
• The precise mechanisms by which anti-B cell therapy combats autoimmunity are not fully understood.

Purpose of the Study:

• To investigate if rituximab resets early B cell tolerance checkpoints in type 1 diabetes patients.
• To analyze the reactivity of B cells before and after rituximab treatment.

Main Methods:

• Analysis of antibody reactivity in single, mature naive B cells from 4 T1D patients.
• Comparison of B cell populations before and 52 weeks after rituximab treatment.

Main Results:

• Rituximab treatment did not change the frequency of autoreactive and polyreactive B cells in T1D patients.
• Elevated levels of autoreactive B cells persisted post-treatment.
• Autoreactive B cells post-treatment were newly generated, not escaped clones.

Conclusions:

• Anti-B cell therapy offers temporary autoimmune dampening via B cell depletion.
• Repopulation with autoreactive B cells likely contributes to disease relapse observed in many autoimmune patients after therapy.